Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort
Autor: | Black, JA, Long, GH, Sharp, SJ, Kuznetsov, L, Boothby, CE, Griffin, SJ, Simmons, RK |
---|---|
Přispěvatelé: | Sharp, Stephen [0000-0003-2375-1440], Boothby, Clare [0000-0001-9396-8333], Griffin, Simon [0000-0002-2157-4797], Simmons, Rebecca [0000-0002-7726-8529], Apollo - University of Cambridge Repository |
Rok vydání: | 2015 |
Předmět: |
Adult
Male Cardiotonic Agents Health Status Endocrinology Diabetes and Metabolism Medication Drug Prescriptions Article HRQoL Cohort Studies Endocrinology Surveys and Questionnaires Internal Medicine Humans Mass Screening Practice Patterns Physicians' Aged digestive oral and skin physiology Diabetes Middle Aged United Kingdom Mental Health Diabetes Mellitus Type 2 Cardiovascular Diseases cardiovascular system Quality of Life Female Diabetic Angiopathies circulatory and respiratory physiology |
Zdroj: | Diabetes Research and Clinical Practice |
ISSN: | 0168-8227 |
DOI: | 10.1016/j.diabres.2015.04.013 |
Popis: | Highlights • We examined individuals with screen-detected diabetes over five years. • Two cardio-protective agents were prescribed at diagnosis, 3 at one year and 4 at five years. • Increases in cardio-protective medication did not impact negatively on HRQoL. Aims Establishing a balance between the benefits and harms of treatment is important among individuals with screen-detected diabetes, for whom the burden of treatment might be higher than the burden of the disease. We described the association between cardio-protective medication and health-related quality of life (HRQoL) among individuals with screen-detected diabetes. Methods 867 participants with screen-detected diabetes underwent clinical measurements at diagnosis, one and five years. General HRQoL (EQ5D) was measured at baseline, one- and five-years, and diabetes-specific HRQoL (ADDQoL-AWI) and health status (SF-36) at one and five years. Multivariable linear regression was used to quantify the association between change in HRQoL and change in cardio-protective medication. Results The median (IQR) number of prescribed cardio-protective agents was 2 (1 to 3) at diagnosis, 3 (2 to 4) at one year and 4 (3 to 5) at five years. Change in cardio-protective medication was not associated with change in HRQoL from diagnosis to one year. From one year to five years, change in cardio-protective agents was not associated with change in the SF-36 mental health score. One additional agent was associated with an increase in the SF-36 physical health score (2.1; 95%CI 0.4, 3.8) and an increase in the EQ-5D (0.05; 95%CI 0.02, 0.08). Conversely, one additional agent was associated with a decrease in the ADDQoL-AWI (−0.32; 95%CI −0.51, −0.13), compared to no change. Conclusions We found little evidence that increases in the number of cardio-protective medications impacted negatively on HRQoL among individuals with screen-detected diabetes over five years. |
Databáze: | OpenAIRE |
Externí odkaz: |